StockWatch
·
MANIPAL HEALTH ENTERPRISES LTD · QQ2 FY-2027 · THE CALL

Record revenue, margin sustains amid integration costs

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsMANIPALHOSManipal Health Enterprises Ltd16 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Reaffirmed 23%–24% Sahyadri margin target (4–5 yr); greenfield bed additions tracking guidance. No FY27 PAT guidance given; avoided over-commitment.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Manipal delivered record revenue (₹3,399 Cr, +37% YoY) with stable 23% OPM and +17% PAT growth—solid operational execution and digital monetization (23% of revenue). However, greenfield/integration costs (Electronic City ₹13 Cr Q2 loss, Gurugram ramp) and government-scheme volatility will suppress near-term upside. Sahyadri is ahead of 4–5 yr margin target, validating expansion thesis, but capex cycle requires 2–3 yr patience.

₹3399.3 Cr

Revenue · +37% YoY

₹285 Cr

Reported PAT · +null% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 revenue of INR3,400 Cr, 37% YoY growth

MET

Delivered ₹3,399.3 Cr; claim matches reported, YoY % not independently verified but consistent with management narrative

Q2 EBITDA INR882 Cr at 26% margin incl. Sahyadri

MET

If EBITDA 882 on 3399.3 revenue, margin = 25.9% ≈ 26%, consistent

Q2 PAT INR639 Cr, 10% margin

OVERSTATED

Delivered Q2 PAT ₹285.0 Cr (8.1% margin). Statement in opening remarks likely referred to H1, not Q2 alone.

Volume-led growth: inpatient +35% YoY, outpatient +27% YoY

MET

Occupancy rose 65% → 70% QoQ, 2.8 days LOS, ARPOB ₹70.6K/day—strong operational metrics align with claim

Sahyadri Q2 revenue INR375 Cr, 13% sequential growth

MET

Sahyadri EBITDA ₹73 Cr, 19.5% margin Q2—improvement over 15.5% FY26, greenfields at 24%–25% already

Earnings quality

What changed since the last call

Deltas vs. the prior call

Greenfield execution timeline extended

Downgrade

Electronic City ramp slower than anticipated; ₹13 Cr EBITDA loss Q2 vs prior expectation of quicker breakeven. Gurugram now 3–4 yr plan vs initially suggested nearer term.

Digital revenue momentum sustained

Upgrade

Digital now 23% of H1 revenue (from prior <15% implied); e-pharmacy 34k orders/qtr, telehealth 38k consultations/qtr.

Sahyadri margin trajectory ahead of curve

Upgrade

Greenfields Kanakapura & Yelahanka already at 24%–25% EBITDA margin <1 yr post-launch; exceeds 4–5 yr guidance.

Occupancy and volume inflection confirmed

Upgrade

Occupancy 65% → 70% QoQ; inpatient +35% YoY, outpatient +27% YoY; ARPOB ₹70.6k/day (+8% YoY).

The Q&A

Analysts pressed hard on Electronic City losses, Sahyadri rate negotiations, government scheme headwind duration, and Tier 2/3 capex ROI. Management held firm on strategic vision, acknowledged costs, but declined to quantify H2/FY28 upside; emphasised 4–5 yr horizon. Tone: confident on fundamentals, cautious on near-term.

The exchanges that mattered

East India cluster performance — Damayanti Kerai, HSBC

Answered

Scheme transition (Swasthya Sathi) created headwind, but revenue robust. Cash & TPA focus ongoing. Dhakuria new oncology team onboarded; expect recovery as clinicians settle.

Oncology exposure & drug capping — Aman Goyal, IIFL Capital

Partial

Onco revenue ~12% of network. Drug capping is small portion of that (controlled drugs). No material impact at scale.

Electronic City EBITDA loss — Aman Goyal, IIFL Capital

Partial

Ramp-up phase. Multi-pronged approach: complexity of work, high-end programs, clinicians adding. Trajectory improving; loss not structural.

Bed addition timeline & capex — Karan Vora, Goldman Sachs

Answered

H2 ~440–550 beds (greenfield + brownfield). Kinder 100 beds end-Q2. FY28 ~100 beds brownfield. Capex fully invested.

Sahyadri margin trajectory — Neha Manpuria, Bank of America

Answered

Reaffirming 23%–24% over 4–5 yr. Teams joining, digital ramping 11%, operating efficiencies. No specific timing on 25%.

Payer mix: Tier 2/3 govt. prevalence — Kunal Randeria, Axis Capital

Answered

Comfortable in 80% range. Focus on cash, TPA, desirable payer mix. Govt. business improving selectively.

Greenfield strategy: Bangalore vs Mumbai/Raipur — Alankar Garude, Kotak Institutional Equities

Answered

Bangalore: densified, micro-market. Mumbai/Raipur: larger footprint, staggered approach. Teams & doc availability different.

Geographic diversification rationale — Aman Kumar Singh, Individual

Answered

Manipal originated in Karnataka 35 yr ago; natural home-market strength. Expanding South, West, East. Focused on tertiary/quaternary care only.

Guidance

Forward guidance and management's confidence

FY27–FY28: 1,000+ new beds ramp Q2–Q4 FY27 onwards

Medium

H2 FY27 ~440–550 beds; FY28 ~100 brownfield. Greenfields (Kanakapura, Yelahanka, Electronics City) show ramp, though timeline extended vs prior expectation.

Sahyadri: 23%–24% EBITDA margin over 4–5 yr from acquisition

High

Already at 19.5% Q2; greenfields at 24%–25% <1 yr. Guidance ahead of curve, being beaten on early ramp.

Portfolio: progressing toward 25% EBITDA margin

Medium

Currently 26% (Q2 incl. Sahyadri). Digital revenue now 23% will help; greenfield losses (Electronic City) temporary headwind.

FY27: ₹2,000 Cr capex (from Q1 implicit); FY28–FY30: ₹4,000 Cr for 3,000-bed capacity

Medium

Major spends: Gurugram, Gurudwara, Raipur, Mumbai new sites. Debt repaid ₹500+ Cr Q2; capex cycle now ramping.

Risks the call surfaced

Ranked by how much they should concern a holder

Greenfield execution

Medium

Electronic City ₹13 Cr Q2 EBITDA loss; Gurugram, Kinder still in ramp. Complexity & clinician availability in new markets delaying margins 1–2 yr beyond initial plan.

Government scheme volatility

Medium

East India Swasthya Sathi reduction; Ayushman Bharat scheme instability. Govt. business 13%–14% of mix; scheme changes create margin/volume noise quarterly.

Sahyadri integration & insurance

Medium

Sahyadri Hospitals Private Limited remains separate entity post-acquisition; insurance contracts need renegotiation (legal entity unchanged). Rate pressures in Pune if entity rebrand happens.

Occupancy and payer mix in Tier 2/3

Medium

Raipur, Mumbai, new greenfields require 2–3 yr to reach 70%+ occupancy. Clinician talent constraints in non-Bangalore metros. Government scheme unpredictability in Tier 2/3.

Capex & debt burden

Low

₹2,000 Cr FY27 capex + ₹4,000 Cr over 3–4 yr plan is capital-intensive. Debt repaid ₹500 Cr Q2, but interest costs remain until maturity. Refinance risk if rates stay elevated.

Management

Score 7/10. Clear on operational metrics (occupancy, volumes, ARPOB), specific on segment performance (Sahyadri 19.5%, greenfields 24%–25%). Transparent on challenges (Electronic City loss, scheme volatility). Cautious on forward guidance (no FY27/FY28 PAT target given) to avoid over-commitment. Track record mixed. Bed addition targets broadly on track but slower than anticipated (Electronic City ramp extended). Sahyadri margin trajectory ahead of 4–5 yr target. Digital revenue momentum (23% of H1) exceeding expectations. Greenfield complexity & capex cycle stretching timeline.

What to watch next
  • 1 · H2 FY27

    Electronic City, Gurugram, Kinder Hotel ramp; 440–550 bed add-ons

  • 2 · FY28 start

    Sahyadri insurance rate negotiations finalize; greenfield breakeven visibility

  • 3 · FY28–FY29

    Gurugram 500-bed tertiary facility onstream; digital monetization scaling

Sahyadri is ahead of 4–5 yr margin target, validating expansion thesis, but capex cycle requires 2–3 yr patience.

Informational and educational content only. Not investment advice.